Allergan, BioMarin Hold Promise for 2018

On Wednesday we highlighted some small-cap names in biotech and biopharma that should have solid performances in 2018. I believe the year should a good one for the industry, provided tax reform passes. After being dormant for over a year, I also expect merger-and-acquisition (M&A) activity across the industry to come roaring back in the New Year. Large drug and biotech giants have a dearth of internal growth opportunities but are flush with cash and have hundreds of billions of dollars stashed in their overseas operations. This combination should mean a lot of small- and mid-cap names will not be stand-alone entities by the end of 2018.

Today, we will throw out a couple of larger-cap names that I think will perform quite well over the next 12 months. Allergan plc (AGN) has been battered the last few months largely due to a self-inflicted wounds incurred while trying to protect and extend the patents of a key drug. Those travails seem more than fully priced into the shares after a 30% decline since summer. Once tax-loss selling ends, I think the stock of Allergan could get off to a good start in 2018....264 more words left in this article. To read them, just click below and try Real Money FREE for 14 days.

Read the full story and get access to the Real Money Pro trading floor.

There’s no substitute for a trading floor to get great ideas, so Jim Cramer created a better one at Real Money and blogs there exclusively. We then added legendary hedge fund manager, Doug Kass, with his exclusive Daily Diary and best investing ideas. Staffed with more than 4 dozen investing pros, money managers, journalists and analysts, Real Money Pro gives you a flood of opinions, analysis and actionable trading advice found nowhere else, and allows you to interact directly with each expert.

Already a Subscriber? Please login.

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.